Literature DB >> 10540708

[A case of pulmonary metastasis from renal cell carcinoma with complete response to interferon-alpha and tegafur/uracil (UFT) but possibly UFT-induced liver dysfunction and leukoencephalopathy-like symptoms].

K Suzuki1, A Nukui, M Kobayashi, Y Sugaya, O Muraishi, T Morita, A Tokue.   

Abstract

A 61-year-old man presented with gross hematuria. He underwent left radical nephrectomy under a diagnosis of left renal cell carcinoma without distant metastasis, but bilateral multiple pulmonary metastases appeared 2.5 months after the operation. Though the metastases responded well to combination therapy of interferon-alpha and a 1:4 mixture of tegafur and uracil (UFT), the side effects of liver dysfunction and leukoencephalopathy-like symptoms due to UFT appeared 7 months after the beginning of the chemotherapy. These side effects were improved after the cessation of UFT administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540708

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  3 in total

1.  Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience.

Authors:  Minoru Kobayashi; Hitoshi Ikeda; Akinori Nukui; Kazumi Suzuki; Yasuhiro Sugaya; Masayuki Yuzawa; Tatsuo Morita
Journal:  Int J Clin Oncol       Date:  2008-06-14       Impact factor: 3.402

2.  Severe Dyspnea due to Pulmonary Metastasis of Renal Cell Carcinoma: Is Cytoreductive Surgery of Value?

Authors:  Mohammad Kazem Moslemi; Seiied Jalal Esshagh Hosseini; Seiied Mohammad Amin Joorabchin
Journal:  Case Rep Oncol       Date:  2010-09-28

3.  Different responses to two types of 5-fluorouracil prodrugs in combination with interferon-alpha in pulmonary metastases of renal cell carcinoma: a case report.

Authors:  Tatsuo Morita; Kazuhiko Nakano; Masayuki Yuzawa
Journal:  Cases J       Date:  2009-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.